How does uber one work

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Zantac (ranitidine) was voluntarily recalled from the U.S. market in April 2020 due to concerns about the presence of N-Nitrosodimethylamine (NDMA), a probable human carcinogen. While the FDA has not definitively concluded that NDMA in ranitidine causes cancer, the presence of this contaminant led to the widespread discontinuation of the drug. Individuals who have concerns about their past use of Zantac should consult with their healthcare provider.

Key Facts

Zantac (ranitidine) was recalled from the U.S. market in April 2020 due to NDMA contamination.
NDMA is classified as a probable human carcinogen by regulatory agencies.
The FDA requested the withdrawal of ranitidine products after NDMA was detected at low levels.
Contamination levels were found to increase over time and under different storage conditions.
Alternative medications like famotidine (Pepcid) and cimetidine (Tagamet) are available and considered safe.

Overview

Zantac, a brand name for the medication ranitidine, was once a widely used over-the-counter and prescription drug for treating and preventing heartburn, indigestion, and other conditions related to excess stomach acid. It belongs to a class of drugs known as H2 blockers (histamine-2 blockers), which work by reducing the amount of acid produced by the stomach. For decades, Zantac was a staple in many medicine cabinets, trusted for its efficacy in providing relief from uncomfortable gastrointestinal symptoms.

However, in recent years, significant concerns have emerged regarding the safety of ranitidine. These concerns primarily stem from the detection of a substance called N-Nitrosodimethylamine (NDMA) in the medication. NDMA is classified as a probable human carcinogen, meaning it is reasonably anticipated to cause cancer in humans. This discovery led to a cascade of regulatory actions and ultimately the discontinuation of Zantac products in many markets, including the United States.

How It Works

Mechanism of Action: Ranitidine functions by blocking histamine-2 receptors in the stomach's parietal cells. Histamine is a natural substance that signals these cells to produce stomach acid. By blocking these receptors, ranitidine effectively reduces the secretion of gastric acid, thereby alleviating symptoms associated with excess acidity.
Acid Reduction: The primary therapeutic effect of Zantac is its ability to decrease the volume and acidity of stomach contents. This reduction in acid helps to prevent irritation of the esophagus and stomach lining, which is the cause of symptoms like heartburn and acid reflux.
Duration of Effect: As an H2 blocker, ranitidine provides relief that typically lasts for several hours, making it suitable for both occasional and more persistent acid-related issues. Its action is more sustained than some antacids, which provide more immediate but shorter-lived relief.
Comparison to Other Acid Reducers: Zantac falls under the H2 blocker category, distinct from proton pump inhibitors (PPIs) like omeprazole, which work by a different and often more potent mechanism of directly inhibiting the acid pumps. H2 blockers were generally considered a first-line treatment for mild to moderate acid-related disorders before the advent of PPIs and before the NDMA concerns.

Key Comparisons

Feature	Zantac (Ranitidine)	Famotidine (Pepcid)
Drug Class	H2 Blocker	H2 Blocker
Primary Use	Heartburn, Acid Indigestion, GERD (historically)	Heartburn, Acid Indigestion, GERD
Availability	Recalled/Discontinued in U.S.	Available Over-the-Counter and Prescription
Key Concern	NDMA Contamination	Generally considered safe, no widespread NDMA concerns

Why It Matters

Health Risks: The discovery of NDMA in ranitidine products raised significant public health concerns. Regulatory bodies like the U.S. Food and Drug Administration (FDA) took action because NDMA is classified as a probable human carcinogen, with studies suggesting it may increase the risk of certain cancers, such as liver, kidney, and stomach cancer, with prolonged exposure.
Regulatory Action: In April 2020, the FDA requested that all ranitidine products be removed from the U.S. market. This decision was based on internal testing and publicly available data that revealed NDMA impurities in ranitidine products, which were found to increase over time and under various storage conditions. This proactive measure aimed to protect consumers from potential exposure to a known carcinogen.
Market Impact and Alternatives: The withdrawal of Zantac left a void in the market for accessible heartburn relief. Fortunately, several effective and safe alternatives remain available. Other H2 blockers, such as famotidine (Pepcid) and cimetidine (Tagamet), continue to be widely used and are considered safe for their intended purposes. Proton pump inhibitors (PPIs) are also readily available and offer a different, often more potent, mechanism for reducing stomach acid.

The situation with Zantac serves as a critical reminder of the ongoing vigilance required in pharmaceutical safety. While medications offer significant health benefits, continuous monitoring and rigorous testing are essential to identify and address potential risks. Consumers are encouraged to stay informed about drug recalls and to consult with their healthcare providers regarding any concerns about their medications or potential alternatives.